Medtronic and Abbott are rewriting the playbook for continuous glucose monitor (CGM)and pump integration, and some of the changes that we never saw coming. The global partnership means that Libre technology from Abbott will now be integrated into Medtronic’s insulin pumps — specifically the MiniMed 780G and possibly the InPen smart insulin pen — giving people with diabetes more sensor choices and better flexibility.

One of the biggest wins: the FDA cleared the MiniMed 780G system to work with Abbott’s new Instinct sensor in type 1 diabetes. This goes beyond just pairing hardware — Medtronic’s SmartGuard algorithm has now been designated an interoperable automated glycemic controller (iAGC), meaning it can operate with sensors built by partners like Abbott. Plus, 780G is now approved for use by adults with insulin-requiring type 2 diabetes, amplifying access.

Then there’s Simplera — Medtronic’s all-on-one disposable CGM. It was already FDA approved, and now the Simplera Sync sensor (also designed to work with 780G) and upcoming Abbott-based sensors will broaden the ways people can monitor their glucose.

What all this means in practice: less dependency on one sensor company, greater compatibility, and more options to match individual preferences — whether that’s for discreet wear, longer sensor life, or more accuracy. It’s a big shift away from “one-size-fits-all” in diabetes tech.

In my latest video (up top), I dive into what this Abbott-Medtronic partnership really looks like when used daily — how Instinct sensor integration works, what Simplera Sync offers, and what’s ahead for patch pumps and hybrid systems. Hit the YouTube button above to see just how much choice is opening up.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.